Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$35.29 - $50.26 $123,515 - $175,910
3,500 Added 194.44%
5,300 $240,000
Q2 2024

Aug 14, 2024

SELL
$35.12 - $64.78 $414,415 - $764,404
-11,800 Reduced 86.76%
1,800 $75,000
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $63,440 - $398,000
8,000 Added 142.86%
13,600 $512,000
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $18,720 - $37,440
3,200 Added 133.33%
5,600 $60,000
Q3 2023

Nov 14, 2023

SELL
$9.56 - $14.0 $138,620 - $203,000
-14,500 Reduced 85.8%
2,400 $24,000
Q2 2023

Aug 14, 2023

SELL
$11.08 - $15.92 $390,016 - $560,384
-35,200 Reduced 67.56%
16,900 $200,000
Q1 2023

May 15, 2023

SELL
$11.25 - $22.21 $88,875 - $175,459
-7,900 Reduced 13.17%
52,100 $630,000
Q4 2022

Feb 14, 2023

BUY
$11.1 - $18.26 $666,000 - $1.1 Million
60,000 New
60,000 $790,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.